The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer
Cholangiocarcinoma is a fatal cancer of the biliary epithelium and has an incidence that is increasing worldwide. Survival beyond a year of diagnosis is less than 5%, and therapeutic options are few. Known risk factors include biliary diseases such as primary sclerosing cholangitis and parasitic inf...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
The Company of Biologists
2013-03-01
|
Series: | Disease Models & Mechanisms |
Online Access: | http://dmm.biologists.org/content/6/2/281 |
id |
doaj-8802c793ab814e5eaa6854774583b635 |
---|---|
record_format |
Article |
spelling |
doaj-8802c793ab814e5eaa6854774583b6352020-11-25T00:14:08ZengThe Company of BiologistsDisease Models & Mechanisms1754-84031754-84112013-03-016228129210.1242/dmm.010561010561The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancerAbigail ZabronRobert J. EdwardsShahid A. KhanCholangiocarcinoma is a fatal cancer of the biliary epithelium and has an incidence that is increasing worldwide. Survival beyond a year of diagnosis is less than 5%, and therapeutic options are few. Known risk factors include biliary diseases such as primary sclerosing cholangitis and parasitic infestation of the biliary tree, but most cases are not associated with any of these underlying diseases. Numerous in vitro and in vivo models, as well as novel analytical techniques for human samples, are helping to delineate the many pathways implicated in this disease, albeit at a frustratingly slow pace. As yet, however, none of these studies has been translated into improved patient outcome and, overall, the pathophysiology of cholangiocarcinoma is still poorly understood. There remains an urgent need for new approaches and models to improve management of this insidious and devastating disease. In this review, we take a bedside-to-bench approach to discussing cholangiocarcinoma and outline research opportunities for the future in this field.http://dmm.biologists.org/content/6/2/281 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Abigail Zabron Robert J. Edwards Shahid A. Khan |
spellingShingle |
Abigail Zabron Robert J. Edwards Shahid A. Khan The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer Disease Models & Mechanisms |
author_facet |
Abigail Zabron Robert J. Edwards Shahid A. Khan |
author_sort |
Abigail Zabron |
title |
The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer |
title_short |
The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer |
title_full |
The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer |
title_fullStr |
The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer |
title_full_unstemmed |
The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer |
title_sort |
challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer |
publisher |
The Company of Biologists |
series |
Disease Models & Mechanisms |
issn |
1754-8403 1754-8411 |
publishDate |
2013-03-01 |
description |
Cholangiocarcinoma is a fatal cancer of the biliary epithelium and has an incidence that is increasing worldwide. Survival beyond a year of diagnosis is less than 5%, and therapeutic options are few. Known risk factors include biliary diseases such as primary sclerosing cholangitis and parasitic infestation of the biliary tree, but most cases are not associated with any of these underlying diseases. Numerous in vitro and in vivo models, as well as novel analytical techniques for human samples, are helping to delineate the many pathways implicated in this disease, albeit at a frustratingly slow pace. As yet, however, none of these studies has been translated into improved patient outcome and, overall, the pathophysiology of cholangiocarcinoma is still poorly understood. There remains an urgent need for new approaches and models to improve management of this insidious and devastating disease. In this review, we take a bedside-to-bench approach to discussing cholangiocarcinoma and outline research opportunities for the future in this field. |
url |
http://dmm.biologists.org/content/6/2/281 |
work_keys_str_mv |
AT abigailzabron thechallengeofcholangiocarcinomadissectingthemolecularmechanismsofaninsidiouscancer AT robertjedwards thechallengeofcholangiocarcinomadissectingthemolecularmechanismsofaninsidiouscancer AT shahidakhan thechallengeofcholangiocarcinomadissectingthemolecularmechanismsofaninsidiouscancer AT abigailzabron challengeofcholangiocarcinomadissectingthemolecularmechanismsofaninsidiouscancer AT robertjedwards challengeofcholangiocarcinomadissectingthemolecularmechanismsofaninsidiouscancer AT shahidakhan challengeofcholangiocarcinomadissectingthemolecularmechanismsofaninsidiouscancer |
_version_ |
1725391437919420416 |